Risk Factors for Serious Prescription Opioid-Induced Respiratory Depression or Overdose: Comparison of Commercially Insured and Veterans Health Affairs Populations

Abstract Objective To characterize the risk factors associated with overdose or serious opioid-induced respiratory depression (OIRD) among medical users of prescription opioids in a commercially insured population (CIP) and to compare risk factor profiles between the CIP and Veterans Health Administ...

Full description

Saved in:
Bibliographic Details
Published inPain medicine (Malden, Mass.) Vol. 19; no. 1; pp. 79 - 96
Main Authors Nadpara, Pramit A, Joyce, Andrew R, Murrelle, E Lenn, Carroll, Nathan W, Carroll, Norman V, Barnard, Marie, Zedler, Barbara K
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.01.2018
Subjects
Online AccessGet full text
ISSN1526-2375
1526-4637
1526-4637
DOI10.1093/pm/pnx038

Cover

More Information
Summary:Abstract Objective To characterize the risk factors associated with overdose or serious opioid-induced respiratory depression (OIRD) among medical users of prescription opioids in a commercially insured population (CIP) and to compare risk factor profiles between the CIP and Veterans Health Administration (VHA) population. Subjects and Methods Analysis of data from 18,365,497 patients in the IMS PharMetrics Plus health plan claims database (CIP) who were dispensed a prescription opioid in 2009 to 2013. Baseline factors associated with an event of serious OIRD among 7,234 cases and 28,932 controls were identified using multivariable logistic regression. The CIP risk factor profile was compared with that from a corresponding logistic regression among 817 VHA cases and 8,170 controls in 2010 to 2012. Results The strongest associations with serious OIRD in CIP were diagnosed substance use disorder (odds ratio [OR] = 10.20, 95% confidence interval [CI] = 9.06–11.40) and depression (OR = 3.12, 95% CI = 2.84–3.42). Other strongly associated factors included other mental health disorders; impaired liver, renal, vascular, and pulmonary function; prescribed fentanyl, methadone, and morphine; higher daily opioid doses; and concurrent psychoactive medications. These risk factors, except depression, vascular disease, and specific opioids, largely aligned with VHA despite CIP being substantially younger, including more females and less chronic disease, and having greater prescribing prevalence of higher daily opioid doses, specific opioids, and most selected nonopioids. Conclusions Risk factor profiles for serious OIRD among US medical users of prescription opioids with private or public health insurance were largely concordant despite substantial differences between the populations in demographics, clinical conditions, health care delivery systems, and clinical practices.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
Disclosure and conflicts of interest: The study was conceived, designed, executed, and reported by the authors, who had sole control over the data set, data analysis, and decision to publish. kaleo, Inc., which developed and manufactures the naloxone auto-injector Evzio, reviewed the final manuscript for proprietary information and did not change or recommend changes to the manuscript. Drs. Zedler, Joyce, and Murrelle are principals of Venebio Group, LLC, which has research and consulting agreements with kaleo, Inc., and Indivior, PLC, and report no additional potential conflicts of interest. All other authors report no potential conflicts of interest.
Funding sources: This research was cofunded by kaleo, Inc. and Venebio Group, LLC, both located in Richmond, Virginia.
ISSN:1526-2375
1526-4637
1526-4637
DOI:10.1093/pm/pnx038